News 06 fév 2024 QUMEA secures investment of 9 million Swiss francs QUMEA has raised funding of 9 million Swiss francs as part of an oversubscribed Series A financing round. With this fresh capital, the digital he...
News 23 avr 2024 Swibrace advances to clinical phase with innovative 3D-printed wrist braces Swibrace, in partnership with the Inselspital in Bern, moves its customized wrist braces into clinical phase, enhancing fracture treatment throug...
News 19 oct 2023 Mimix Biotherapeutics’ breakthrough tissue regeneration treatment receives strategic investment Biel-based Mimix Biotherapeutics announced the closure of a significant investment round, drawing participation from both European and Asian inve...
News 29 nov 2023 Western Switzerland medtech start-ups embark on human trials Medtech start-ups from Western Switzerland are making significant strides in healthcare, bringing forth innovative solutions for critical medical...
News 14 nov 2023 Opening of the Dynamic Imaging Center at sitem-insel in Bern sitem-insel has inaugurated the Dynamic Imaging Center, a groundbreaking facility that introduces a novel approach to X-ray imaging.
News 23 nov 2023 biped.ai secures CHF 1.2 million for US expansion and European growth Lausanne-based start-up biped.ai, known for its revolutionary technology aiding the visually impaired, has successfully raised CHF 1.2 million.
News 15 nov 2023 Aktiia’s blood pressure monitoring technology advances global cardiovascular research Neuchâtel start-up Aktiia, a pioneer in cuffless blood pressure monitoring, has embarked on a groundbreaking study in collaboration with eminent ...
News 04 déc 2023 Bern University of Applied Sciences launches the Institute for Patient-Centered Digital Health The Bern University of Applied Sciences is set to enhance its foothold in medical informatics with the establishment of a new institute dedicated...
News 29 nov 2023 Meditron, EPFL’s new Large Language Model for medical knowledge EPFL researchers have unveiled Meditron, a groundbreaking open-source Large Language Model (LLM) specifically tailored for the medical field.
ニュース 10 fév 2021 バイオポールがライフサイエンス特化の3施設を2024年までにオープン スイス・イノベーション・パーク・ネットワーク・ウエスト EPFLに属するバイオポールが、3棟の新施設建設で拡大を続けています。新施設はライフサイエンス分野に特化し、2024年までに関連企業の入居用に23万㎡のオフィススペースと研究施設が整備される予定です。
News 11 oct 2023 SFITS, the Swiss Foundation for Innovation and Training in Surgery In the intricate, ever-evolving realm of medical science, the Swiss Foundation for Innovation and Training in Surgery (SFITS) is the platform whe...
News 03 nov 2023 A new gel offers targeted relief for ulcerative colitis patients Researchers at the University of Bern have developed a lipid gel for direct, localized treatment of ulcerative colitis, aiming to reduce side eff...
News 17 oct 2023 Voltiris, Limula, and Parithera secure Biopôle’s Start-Up Fund Vaud-based start-ups Voltiris, Limula, and Parithera gain momentum in their innovative ventures as they secure vital funding and support from Bio...
News 10 mar 2021 Researchers from Bern developed an approach to predict cancer therapy success Scientists from the University and Inselspital of Bern have established organoid culture models from prostate tumor biopsies. These are small clu...
Actualités 18 mai 2021 Le Start-Up Fund du Biopôle veut favoriser un accès précoce à l’innovation dans les sciences de la vie Biopôle a annoncé le lancement du « Biopôle Start-Up Fund », un nouveau fonds dédié au soutien de la prochaine génération d’entrepreneurs dans le...
Actualités 23 mar 2021 Tech4Eva, le premier accélérateur suisse de start-ups consacré à la santé des femmes L’EPFL Innovation Park et le Groupe Mutuel s’associent pour lancer Tech4Eva, le premier programme d’accélération de start-ups en Suisse consacré ...
News 07 aoû 2023 Longevity start-up EPITERNA raises EUR 10 million to slow ageing and extend lifespan Vaud-based longevity start-up EPITERNA has secured EUR 10 million in funding from Prima Materia, an investment firm founded by Spotify founder Da...
Actualités 08 mar 2021 Debiopharm signe un contrat de plus de EUR 900 millions avec Merck Debiopharm a accordé une licence mondiale exclusive au géant pharmaceutique Merck pour le développement et la commercialisation de son médicament...